.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Deloitte
Citi
Baxter
Mallinckrodt
Express Scripts
Accenture
McKinsey
Julphar
Daiichi Sankyo

Generated: November 20, 2017

DrugPatentWatch Database Preview

Leo Labs Company Profile

« Back to Dashboard

What is the competitive landscape for LEO LABS, and what generic alternatives to LEO LABS drugs are available?

LEO LABS has one approved drug.

There are eleven US patents protecting LEO LABS drugs on LEO LABS drugs in the past three years.

There are forty-six patent family members on LEO LABS drugs in twenty-four countries and fourteen supplementary protection certificates in ten countries.

Summary for Leo Labs

International Patents:46
US Patents:11
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-001Jan 23, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-001Jan 23, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Leo Labs
PICATO
ingenol mebutate
GEL;TOPICAL202833-001Jan 23, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for LEO LABS drugs

Drugname Dosage Strength Tradename Submissiondate
ingenol mebutate
Gel0.05%
PICATO
1/27/2016

Non-Orange Book Patents for Leo Labs

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,603,822Therapeutic compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Leo Labs Drugs

Country Document Number Estimated Expiration
Portugal1015413► Subscribe
Norway20083150► Subscribe
BrazilPI0619919► Subscribe
Brazil9811327► Subscribe
Luxembourg92185► Subscribe
Mexico2008007685► Subscribe
Japan2009519314► Subscribe
Australia8721798► Subscribe
South Korea101593579► Subscribe
South Africa200805187► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Leo Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00592Netherlands► SubscribePRODUCT NAME: INGENAN OF EEN DERIVAAT (ZOUT OF ESTER) DAARVAN; REGISTRATION NO/DATE: EU/1/12/796/001-002 20121115
2014 00042Denmark► SubscribePRODUCT NAME: INGENOLMEBUTAT ELLER ET DERIVAT (SALT ELLER ESTER) DERAF); REG. NO/DATE: EU/1/12/796/001-002 20121115
1988877/01Switzerland► SubscribePRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: SWISSMEDIC 62763 12.06.2013
5Finland► Subscribe
2013 00024Denmark► Subscribe
2014030Lithuania► SubscribePRODUCT NAME: INGENOLI MEBUTATUM; REGISTRATION NO/DATE: EU/1/'12/796/001, 2012 11 15 EU/1/12/796/002 20121115
1015413/01Switzerland► SubscribePRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: SWISSMEDIC 62763 12.06.2013
90022-0Sweden► SubscribePRODUCT NAME: INGENAN ELLER ETT DERIVAT (SALT ELLER ESTER) DAERAV; REG. NO/DATE: EU/1/12/796/001 20121115
0682Netherlands► SubscribePRODUCT NAME: INGENOLMEBUTAAT OF EEN DERIVAAT (ZOUT OF ESTER) DAARVAN; REGISTRATION NO/DATE: EU/1/12/796 20121119
185Luxembourg► SubscribePRODUCT NAME: INGENANE OU UN DERIVE(SEL OU ESTER)DE CELUI-CI
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Johnson and Johnson
Dow
Cipla
Mallinckrodt
Cerilliant
Queensland Health
Moodys
Medtronic
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot